Phase 3
Completed N=111
Cocaine/Crack and Reduction of Compulsion With Biperiden
Cocaine Dependence
Source: ClinicalTrials.gov NCT01251393 ↗
Enrolled (actual)
111
Serious AEs
0.0%
Results posted
Feb 2020
Primary outcomePrimary: Compulsion — 5.9; 5.5 score on a scale — p=<0.05
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
Considering the effects of the cholinergic system on the drug reward and self-administration mechanisms, acetylcholine (Ach) may play an important role on cocaine dependence process. Then the present study aims to evaluate biperiden efficacy (a cholinergic antagonist) in attenuate compulsion, one o the main symptoms of the drug dependence.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Compulsion |
5.9; 5.5 | <0.05 sig |
Eligibility Criteria
Inclusion Criteria
- Cocaine or crack dependence, according to the DSM-IV criteria (APA, 1994)
Exclusion Criteria
- Being under treatment with psychoactive drugs
- Have been diagnosed for other Psychiatric Disorders
- Have dependence diagnosis for other drugs, except for tabacco
Data sourced from ClinicalTrials.gov (NCT01251393). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.